Line 51: | Line 51: | ||
overflow:hidden; | overflow:hidden; | ||
} | } | ||
− | #slide ul{width: | + | #slide ul{width:300%;height:100%;transition:1s;} |
#slide ul:after{content:"";display:block;clear:both;} | #slide ul:after{content:"";display:block;clear:both;} | ||
− | #slide li{float:left;width: | + | #slide li{float:left;width:33.333%;height:100%;} |
#slide li:nth-child(1){ | #slide li:nth-child(1){ | ||
Line 61: | Line 61: | ||
} | } | ||
#slide li:nth-child(3){ | #slide li:nth-child(3){ | ||
− | |||
− | |||
− | |||
} | } | ||
Line 72: | Line 69: | ||
#pos2:checked~ul{margin-left:-100%;} | #pos2:checked~ul{margin-left:-100%;} | ||
#pos3:checked~ul{margin-left:-200%;} | #pos3:checked~ul{margin-left:-200%;} | ||
− | |||
#pos1:checked~.pos>label:nth-child(1){background:#666;} | #pos1:checked~.pos>label:nth-child(1){background:#666;} | ||
#pos2:checked~.pos>label:nth-child(2){background:#666;} | #pos2:checked~.pos>label:nth-child(2){background:#666;} | ||
#pos3:checked~.pos>label:nth-child(3){background:#666;} | #pos3:checked~.pos>label:nth-child(3){background:#666;} | ||
− | |||
.mSHdiv{ | .mSHdiv{ | ||
Line 122: | Line 117: | ||
<input type="radio" name="pos" id="pos2"> | <input type="radio" name="pos" id="pos2"> | ||
<input type="radio" name="pos" id="pos3"> | <input type="radio" name="pos" id="pos3"> | ||
− | |||
<ul> | <ul> | ||
− | |||
<li><a href="https://2018.igem.org/Team:BioMarvel/Public_Engagement"><img src="https://static.igem.org/mediawiki/2018/7/76/T--Biomarvel--Banner2_1.png" style="width: 100%; height: 100%"></a></li> | <li><a href="https://2018.igem.org/Team:BioMarvel/Public_Engagement"><img src="https://static.igem.org/mediawiki/2018/7/76/T--Biomarvel--Banner2_1.png" style="width: 100%; height: 100%"></a></li> | ||
<li><a href="https://2018.igem.org/Team:BioMarvel/Project/Description"><img src="https://static.igem.org/mediawiki/2018/7/7f/T--Biomarvel--Banner3.png" style="width: 100%; height: 100%"></a></li> | <li><a href="https://2018.igem.org/Team:BioMarvel/Project/Description"><img src="https://static.igem.org/mediawiki/2018/7/7f/T--Biomarvel--Banner3.png" style="width: 100%; height: 100%"></a></li> | ||
− | + | <li><a><img src="https://static.igem.org/mediawiki/2018/4/49/T--Biomarvel--Banner0.png" style="width: 100%; height: 100%"></a></li> | |
</ul> | </ul> | ||
<p class="pos" style="padding-top: 2em;padding-bottom: 1em; margin: 0;"> | <p class="pos" style="padding-top: 2em;padding-bottom: 1em; margin: 0;"> | ||
Line 133: | Line 126: | ||
<label for="pos2"></label> | <label for="pos2"></label> | ||
<label for="pos3"></label> | <label for="pos3"></label> | ||
− | |||
</p> | </p> | ||
</div> | </div> |
Revision as of 08:32, 25 November 2018
Abstract
The goal of this project is to construct a novel fusion protein of gold binding polypeptides (GBP)-protein G (ProG) to develop an electrochemical biosensor for rapid and simple diagnosis and monitoring heart failure.
DH5-alpha E. coli strain was transformed by a genetically modified recombinant vector coding GBP and ProG. The GBP-ProG fusion protein was derived from the strain with IPTG-induced expression and purified using the TALON metal affinity resin. The resulting GBP-ProG was directly self-immobilized onto gold surfaces via the GBP portion, followed by the oriented binding of antibodies onto the ProG domain targeting the Fc region of antibodies.
An electrochemical immunochip was fabricated through the GBP-ProG and gold patterned interdigitated array electrode. Antibody immobilization onto the gold surface of the electrode by the GBP-ProG was rapidly and simply achieved with proper antibody orientation. This immunochip could be used for diagnosis and monitoring of heart failure.